Stockholders’ Equity - Narrative (Details) $ / shares in Units, $ in Millions				3 Months Ended
	Jul. 10, 2023 USD ($) $ / shares shares	Jun. 16, 2022 USD ($) shares	Apr. 06, 2022 USD ($) $ / shares shares	Mar. 31, 2024 USD ($) $ / shares shares	Mar. 31, 2023 shares	Jan. 02, 2024 USD ($) $ / shares shares	Dec. 31, 2023 $ / shares shares	Dec. 31, 2022 shares	Apr. 08, 2022 USD ($)
Class of Stock [Line Items]
Preferred shares, shares authorized (in shares)				2,000,000			2,000,000
Preferred shares, par value (in dollars per share) | $ / shares				$ 0.0001			$ 0.0001
Preferred shares, shares issued (in shares)				15,000			15,000
Preferred shares, shares outstanding (in shares)				15,000			15,000
Common shares, shares authorized (in shares)				170,000,000			170,000,000
Common shares, par value (in dollars per share) | $ / shares				$ 0.0001			$ 0.0001
Common shares, shares outstanding (in shares)				29,556,474	12,552,673		29,130,607
Common shares, shares issued (in shares)				29,556,474			29,130,607
Exercise of employee stock options, net of tax (in shares)				0	0
COMMON STOCK
Class of Stock [Line Items]
Common shares, shares outstanding (in shares)				29,556,474	12,552,673		29,130,607	12,163,673
Term loan | Term loan
Class of Stock [Line Items]
Common stock issuable upon exercise of pre-funded warrants (in shares)						191,096
Exercise price of warrant (in dollars per share) | $ / shares						$ 1.83
Fair value of warrant | $						$ 0.2
PIPE Purchase Agreement Pre-Funded Warrant
Class of Stock [Line Items]
Warrants exercised (in shares)				0	389,000
Armistice Warrant Agreement
Class of Stock [Line Items]
Common stock issuable upon exercise of pre-funded warrants (in shares)	9,900,990
Exercise price of warrant (in dollars per share) | $ / shares	$ 1.39
Proceeds from Issuance of Common Stock in connection with exercise of Prior Warrant and Pre-Funded Warrants | $	$ 13.8
Armistice Reload Warrant Agreement
Class of Stock [Line Items]
Common stock issuable upon exercise of pre-funded warrants (in shares)	3,750,000
Exercise price of warrant (in dollars per share) | $ / shares	$ 5.13
Warrant expiration period	54 months
Ownership limitation percentage	0.0999
Letter Agreement
Class of Stock [Line Items]
Period after issuance, shares cannot be sold	45 days
Minimum purchase price (in dollars per share) | $ / shares	$ 6.25
Extended expiration date	1 year
At-the-Market Offering | COMMON STOCK
Class of Stock [Line Items]
Issuance of common stock (in shares)				358,210
Series X Convertible Preferred Stock
Class of Stock [Line Items]
Interest rate percentage			1.00%
Common stock trading price (in dollars per share) | $ / shares			$ 22.00
Common stock trading period			30 days
Accreted amount | $				$ 0.2
Conversion price (in dollars per share) | $ / shares			$ 11.00
Convertible preferred stock (in shares)			91
Outstanding common stock, percentage			9.90%
Outstanding common stock, not to exceed, percentage			19.90%
Percentage of investment owned			50.00%
Maximum working capital line | $			$ 5.0
Consideration received | $			15.0
Stock issuance costs | $			0.1
Proceeds from sale of equity, net | $			14.9
Da Vita Healthcare Partners Inc | Share Issuance, Tranche One
Class of Stock [Line Items]
Proceeds from issuance of convertible preferred stock | $		$ 7.5	7.5
Da Vita Healthcare Partners Inc | Series X Convertible Preferred Stock | Private Placement
Class of Stock [Line Items]
Sale of stock, aggregate consideration authorized | $			$ 15.0
Common stock trading price (in dollars per share) | $ / shares			$ 1,000
Da Vita Healthcare Partners Inc | Series X Convertible Preferred Stock | Private Placement | Share Issuance, Tranche One
Class of Stock [Line Items]
Number of shares issued (in shares)		7,500	7,500
Cantor Fitzgerald & Co | At-the-Market Offering
Class of Stock [Line Items]
Sale of stock, aggregate consideration authorized | $				10.4					$ 12.2
Cantor Fitzgerald & Co | Controlled Equity Offering
Class of Stock [Line Items]
Consideration received | $				$ 0.6